Article
Oncology
Eric Feng, Nicholas R. Rydzewski, Meng Zhang, Arian Lundberg, Matthew Bootsma, Kyle T. Helzer, Joshua M. Lang, Rahul Aggarwal, Eric J. Small, David A. Quigley, Martin Sjostrom, Shuang G. Zhao
Summary: In this study, the researchers identified the intrinsic molecular subtypes of metastatic castration-resistant prostate cancer (mCRPC) and assessed their molecular and clinical correlates using a large cohort with gene expression data. The results showed the heterogeneity of mCRPC beyond currently accepted molecular phenotypes, emphasizing the need for transcriptome-wide profiling in future studies to understand the impact of these differences on treatment responses and outcomes.
CLINICAL CANCER RESEARCH
(2022)
Article
Urology & Nephrology
Ravi A. Madan, Fatima H. Karzai, Munjid Al Harthy, Daniel P. Petrylak, Joseph W. Kim, Philip M. Arlen, Inger Rosner, Marc R. Theoret, Lisa Cordes, Marijo Bilusic, Cody J. Peer, Nancy A. Dawson, Anna Couvillon, Amy Hankin, Moniquea Williams, Guin Chun, Helen Owens, Jennifer L. Marte, Min-Jung Lee, Yusuke Tomita, Akira Yuno, Jane B. Trepel, Sunmin Lee, Seth M. Steinberg, James L. Gulley, William D. Figg, William L. Dahut
Summary: The study evaluated the safety and efficacy of cabozantinib combined with docetaxel in mCRPC patients. Cabozantinib was found to be safely added to docetaxel treatment with potential enhanced efficacy. However, due to limited patient accrual, the phase 2 study was terminated early.
Article
Oncology
Wei Ning, Pengkang Chang, Ji Zheng, Fan He
Summary: This case report highlights the potential effectiveness and safety of a second docetaxel rechallenge as a later-line treatment strategy for patients with mCRPC who are concerned about the high costs of multigene molecular testing and PARP inhibitors, as well as repeated prostate needle biopsy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Atefeh Deris, Mahdi Sohrabi-Haghighat
Summary: Patients with mCRPC are classified into three groups based on their response to Abiraterone treatment: best responder, responder, and non-responder. Drug-resistant cells may hinder successful outcomes in the latter two groups. To overcome this challenge, a combination of Docetaxel and Abiraterone is proposed to control both the overall cancer cell population and the drug-resistant subpopulation. Evolutionary Game Theory (EGT) is used as a mathematical modeling approach to study the competition and evolution of mCRPC cancer phenotypes.
Article
Urology & Nephrology
Kristine Kreis, Dirk Horenkamp-Sonntag, Udo Schneider, Jan Zeidler, Gerd Glaeske, Lothar Weissbach
Summary: This study examined real-world haematological toxicity, overall survival, and treatment characteristics of docetaxel and cabazitaxel chemotherapy in mCRPC patients. The findings suggest that cabazitaxel treatment poses higher risk of haematological toxicities and shorter survival time, emphasizing the importance of strict indications when using cabazitaxel in mCRPC patients.
Article
Oncology
Ivan de Kouchkovsky, Arpit Rao, Benedito A. Carneiro, Li Zhang, Catriona Lewis, Audrey Phone, Eric J. Small, Terence Friedlander, Lawrence Fong, Pamela L. Paris, Charles J. Ryan, Russell Z. Szmulewitz, Rahul Aggarwal
Summary: This study evaluated the safety and efficacy of ribociclib plus docetaxel in metastatic castration-resistant prostate cancer (mCRPC). The results showed that the combination treatment achieved a 6-month radiographic progression-free survival (rPFS) rate of 65.8% and a median rPFS of 8.1 months. Genomic profiling of circulating tumor cells (CTCs) suggested that nonamplified MYC was associated with longer rPFS.
CLINICAL CANCER RESEARCH
(2022)
Article
Urology & Nephrology
David Lorente, Casilda Llacer, Rebeca Lozano, Guillermo de Velasco, Nuria Romero-Laorden, Miguel Rodrigo, Angel Sanchez-Iglesias, Carlos di Capua, Elena Castro, Carlos Ferrer, Alfredo Sanchez-Hernandez, David Olmos
Summary: This study validated the prognostic value of the Armstrong risk model in patients treated with first-line androgen receptor signaling inhibitors, showing that low-risk patients received the greatest benefit. Further research is needed to establish the role of Armstrong risk groups for treatment selection in mCRPC patients.
Article
Medicine, General & Internal
Oliver Sartor, Johann de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El-Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, Wendy J. Perez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause
Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Li-Wen Chang, Sheng-Chun Hung, Jian-Ri Li, Kun-Yuan Chiu, Cheng-Kuang Yang, Chuan-Shu Chen, Kevin Lu, Cheng-Che Chen, Shu-Chi Wang, Chia-Yen Lin, Chen-Li Cheng, Yen-Chuan Ou, Shun-Fa Yang, Chiann-Yi Hsu, Szu-Hang Ho, Shian-Shiang Wang
Summary: The study investigated the prognostic efficacy of the Geriatric Nutritional Risk Index (GNRI) in patients with metastatic Castration-resistant Prostate Cancer (mCRPC) receiving docetaxel as the first line of treatment. It was found that poor nutritional status, indicated by a GNRI <92, was associated with shorter progression free survival and overall survival. Additionally, metastatic volume and cumulative docetaxel dosage were identified as independent prognostic factors in overall survival.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Yasemin Sanli, Duygu Has Simsek, Oner Sanli, Rathan M. Subramaniam, Ayse Tuba Kendi
Summary: Lu-177-PSMA therapy shows promising clinical efficacy in patients with mCRPC, with predictors of efficacy being significant. Ongoing clinical trials, including a phase III multicenter FDA registration trial, are currently being conducted in the United States.
Article
Oncology
Kim N. Chi, Dana Rathkopf, Matthew R. Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos, Ji Youl Lee, Eric J. Small, Andrea J. Pereira De Santana Gomes, Guilhem Roubaud, Marniza Saad, Bogdan Zurawski, Valerii Sakalo, Gary E. Mason, Peter Francis, George Wang Ms, Daphne Wu, Brooke Diorio, Angela Lopez-Gitlitz, Shahneen Sandhu
Summary: This study investigated the efficacy of niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC and HRR gene alterations. The results showed that the combination therapy significantly prolonged radiographic progression-free survival compared to abiraterone acetate plus prednisone alone. The treatment was well tolerated with manageable adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Sandy Srinivas
Summary: Significant advancements in the management of mCRPC include the development of newer imaging methods utilizing PSMA PET and radionuclide ligands, as well as the use of PARP inhibitors and Cabazitaxel in treatment. Investigators are focusing on sequencing therapies based on previous exposure to optimize treatment choices for mCRPC patients.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Review
Pharmacology & Pharmacy
Junru Chen, Yaowen Zhang, Xingming Zhang, Jinge Zhao, Yuchao Ni, Sha Zhu, Ben He, Jindong Dai, Zhipeng Wang, Zilin Wang, Jiayu Liang, Xudong Zhu, Pengfei Shen, Hao Zeng, Guangxi Sun
Summary: This study compares the efficacy and safety of systemic treatments in mCRPC patients who have failed docetaxel. The results suggest that enzalutamide may offer the most significant survival benefits and satisfying safety, while cabazitaxel is effective in post-docetaxel settings but associated with a high risk of SAEs.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Cell Biology
Vincenza Conteduca, Alessandra Mosca, Nicole Brighi, Ugo de Giorgi, Pasquale Rescigno
Summary: Prostate cancer is a common cancer in men and patients may develop metastatic disease after radical treatments. Prognostic biomarkers are urgently needed to define patients' risk of cancer-related death.
Article
Oncology
Axel S. Merseburger, Gerhardt Attard, Lennart astroem, Vsevolod B. Matveev, Sergio Bracarda, Adil Esen, Susan Feyerabend, Elzbieta Senkus, Marta Lopez-Brea Piqueras, Gunther Boysen, Georgia Gourgioti, Karla Martins, Simon Chowdhury
Summary: The study found that continuing enzalutamide with docetaxel and androgen deprivation therapy can delay progression in men with mCRPC, supporting the idea that enzalutamide maintenance may control persistent androgen-dependent clones.
Article
Clinical Neurology
Angela Sekely, Lori J. Bernstein, Kristin L. Campbell, Warren P. Mason, Normand Laperriere, Navya Kalidindi, Rosemarylin Or, Ronald Ramos, Seth A. Climans, Gregory R. Pond, Barbara Ann Millar, David Shultz, Derek S. Tsang, Gelareh Zadeh, Kim Edelstein
Summary: This study found that individuals with glioblastoma (GBM) are at risk of neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms shortly after diagnosis. Depressive symptoms were significantly associated with neurocognitive impairment, highlighting the importance of early identification and treatment of depression in GBM patients.
NEURO-ONCOLOGY PRACTICE
(2023)
Article
Oncology
E. K. Donovan, G. R. Pond, H. Seow, P. M. Ellis, A. Swaminath
Summary: This study aimed to evaluate the risk of cardiac toxicity in advanced lung cancer patients after radical radiotherapy. Patients with stage III non-small cell lung cancer (NSCLC) receiving chemoradiotherapy were included from a population-based cohort in Ontario, Canada. The primary outcome was cardiac toxicity, assessed as cardiac events or congestive heart failure, at 1 and 5 years post-chemoradiotherapy. Secondary outcomes included overall survival, survival in relation to post-treatment cardiac events, and the impact of radiotherapy technique on cardiac toxicity. The results showed that the cumulative incidence of cardiac toxicity at 5 years was 20.3% (18.4-22.3) in the NSCLC patients. Median survival was shorter in NSCLC patients who experienced a cardiac event post-chemoradiotherapy compared to those who did not. There was a trend towards increased cumulative cardiac toxicity with three-dimensional conformal radiotherapy compared to other techniques. In conclusion, there is a high risk of cardiac events and congestive heart failure 5 years after radical thoracic radiotherapy, and survival is inferior in patients who experience a cardiac event post-treatment. More conformal radiotherapy techniques may help reduce cardiac toxicity. Further studies should explore adaptive treatment planning and close monitoring and intervention in this high-risk group after chemoradiotherapy.
Article
Oncology
Ana-Alicia Beltran-Bless, Mark J. Clemons, Christian Fesl, Richard Greil, Gregory R. Pond, Marija Balic, Lisa Vandermeer, Vesna Bjelic-Radisic, Christian F. Singer, Guenther G. Steger, Ruth Helfgott, Daniel Egle, Lidija Soelkner, Simon P. Gampenrieder, Stephanie Kacerovsky-Strobl, Christoph Suppan, Magdalena Ritter, Gabriel Rinnerthaler, Georg Pfeiler, Hannes Fohler, Dominik Hlauschek, John Hilton, Michael Gnant
Summary: The impact of early treatment cessation on adjuvant bisphosphonate therapy for postmenopausal early breast cancer patients was evaluated. The study found that the number of bisphosphonate infusions had no significant association with breast cancer-specific outcomes. Further research is needed to define optimal regimens of adjuvant bone-targeted therapies.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Ranjan Sur, Gregory Pond, Conrad Falkson, Ming Pan, James Wright, Andrea Bezjak, Anne Dagnault, Edward Yu, Maha Almahmudi, Serge Puksa, Darin Gopaul, Theos Tsakiridis, Anand Swaminath, Peter Ellis, Timothy Whelan
Summary: The purpose of this study was to evaluate the potential clinical benefit of adding high-dose-rate intraluminal brachytherapy (HDRIB) to external beam radiation therapy (EBRT) for patients with advanced non-small cell lung cancer (NSCLC). The results showed small to moderate improvements in symptom relief with combined therapy, but they did not reach statistical significance. Further research is needed before recommending HDRIB in addition to EBRT for palliation of lung cancer symptoms.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Justin M. McGinnis, Gregory R. Pond, Clare J. Reade, Kara L. Schnarr, Marko Simunovic, Lorraine M. Elit, Hsien-Yeang Seow, Limor Helpman
Summary: This study aimed to assess the uptake of minimally invasive hysterectomy among patients with endometrial and cervical cancer in Ontario, Canada, and evaluate the associations with various factors. The study found that the uptake of minimally invasive surgery increased over time, but its receipt was influenced by social determinants, provider variables, and systems factors.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Talal El Zarif, Amin H. Nassar, Gregory R. Pond, Tony Zibo Zhuang, Viraj Master, Bassel Nazha, Scot Niglio, Nicholas Simon, Andrew W. Hahn, Curtis A. Pettaway, Shi-Ming Tu, Noha Abdel-Wahab, Maud Velev, Ronan Flippot, Sebastiano Buti, Marco Maruzzo, Arjun Mittra, Jinesh Gheeya, Yuanquan Yang, Pablo Alvarez Rodriguez, Daniel Castellano, Guillermo de Velasco, Giandomenico Roviello, Lorenzo Antonuzzo, Rana R. Mckay, Bruno Vincenzi, Alessio Cortellini, Gavin Hui, Alexandra Drakaki, Michael Glover, Ali Raza Khaki, Edward El-Am, Nabil Adra, Tarek H. Mouhieddine, Vaibhav Patel, Aida Piedra, Angela Gernone, Nancy B. Davis, Harrison Matthews, Michael R. Harrison, Ravindran Kanesvaran, Giulia Claire Giudice, Pedro Barata, Alberto Farolfi, Jae Lyun Lee, Matthew Milowsky, Charlotte Stahlfeld, Leonard Appleman, Joseph W. Kim, Dory Freeman, Toni K. Choueiri, Philippe E. Spiess, Andrea Necchi, Andrea B. Apolo, Guru P. Sonpavde
Summary: This study investigated the clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors. The results showed that immune checkpoint inhibitors are active in a subset of patients with penile squamous cell carcinoma. Future studies are needed to identify patients who are more likely to benefit from this treatment.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Medicine, General & Internal
Timothy J. Whelan, Sally Smith, Sameer Parpia, Anthony W. Fyles, Anita Bane, Fei-Fei Liu, Eileen Rakovitch, Lynn Chang, Christiaan Stevens, Julie Bowen, Sawyna Provencher, Valerie Theberge, Anna Marie Mulligan, Zuzana Kos, Mohamed A. Akra, K. David Voduc, Tarek Hijal, Ian S. Dayes, Gregory Pond, James R. Wright, Torsten O. Nielsen, Mark N. Levine
Summary: Among women with T1N0 grade 1 or 2 luminal A breast cancer who had undergone breast-conserving surgery and received endocrine therapy, the incidence of local recurrence at 5 years was low without radiotherapy.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Meeting Abstract
Oncology
Vanessa Lopez Ozuna, Gregory R. Pond, John Ms Bartlett, Lazlo Radvanyi, Melanie Spears, Teresa Petrocelli, Carol Gordon, Rebecca J. Rose, Angel Arnaout
Meeting Abstract
Oncology
Angel Arnaout, Susan Robertson, Kianoosh Keyhanian, Megan Hopkins, Linda Liao, Vida Talebian, Arif Awan, John M. S. Bartlett, Gregory R. Pond, Lazlo Radvanyi, Lewis H. Bender, Ian B. Walters, Vanessa Lopez Ozuna, Melanie Spears
Meeting Abstract
Oncology
John M. S. Bartlett, Keying Xu, Jenna Wong, Gregory R. Pond, Yi Zhang, Melanie Spears, Ranelle Salunga, Elizabeth Mallon, Karen J. Taylor, Annette Hasenburg, Christos Markopoulos, Luc Dirix, Caroline Seynaeve, Cornelis J. H. van de Velde, Daniel Rea, Catherine A. Schnabel, Kai Treuner, Jane Bayani
Article
Oncology
Christa Aubrey, Gregory R. Pond, Limor Helpman, Danielle Vicus, Laurie Elit, Marie Plante, Susie Lau, Janice S. Kwon, Alon D. Altman, Karla Willows, Tomer Feigenberg, Jeanelle Sabourin, Vanessa Samouelian, Laurence Bernard, Norah Cockburn, Nora-Beth Saunders, Sabrina Piedimonte, Ly-Ann Teo-Fortin, Soyoun Rachel Kim, Noor Sadeq, Ji-Hyun Jang, Sarah Shamiya, Gregg Nelson
Summary: Minimally invasive surgery for macroscopic cervical cancer leads to worse outcomes than open surgery, but preoperative conization may help mitigate the risk. This retrospective study examined oncologic outcomes in cervical cancer cases treated initially with conization and subsequent hysterectomy using either minimally invasive or open approaches. The study found no significant differences in recurrence-free survival or overall survival between the two surgical approaches. However, further studies are needed to confirm these findings.
Article
Biochemistry & Molecular Biology
Elham Ahmadi, Simon Wang, Mohammad Gouran-Savadkoohi, Georgia Douvi, Naghmeh Isfahanian, Nicole Tsakiridis, Brent E. Faught, Jean-Claude Cutz, Monalisa Sur, Satish Chawla, Gregory R. Pond, Gregory R. Steinberg, Ian Brown, Theodoros Tsakiridis
Summary: Metabolic dysregulation is an early event in carcinogenesis, and PSMA may serve as an independent predictor for early prostate cancer progression. This study suggests that the expression of metabolic enzymes detected by immunohistochemistry in baseline diagnostic prostate biopsies may be valuable in assessing the risk of rapid progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Meeting Abstract
Oncology
F. DiPastena, G. Pond, E. Ahmadi, E. E. Tsakiridis, G. R. Steinberg, T. Tsakiridis
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Meeting Abstract
Oncology
Talal El Zarif, Amin Nassar, Lijuan Jiang, Gregory Russell Pond, Tony Zhuang, Maud Velev, Andrew Warren Hahn, Sebastiano Buti, Pablo Alvarez, Rana R. Mckay, Bruno Vincenzi, Edward El-Am, Gavin Hui, Jae-Lyun Lee, Tarek H. Mouhieddine, Matthew I. Milowsky, Harrison Matthews, Pedro C. Barata, Andrea B. Apolo, Guru P. Sonpavde
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Aly-Khan A. Lalani, Anand Swaminath, Gregory Russell Pond, Scott C. Morgan, Arun Azad, William Chu, Anil Kapoor, Michael Bonert, Jonathan L. Bramson, Michael G. Surette, Dominick Bosse, Shankar Siva, Georg A. Bjarnason, Darin Gopaul, Naveen S. Basappa, Jim Wright, Sebastien J. Hotte
JOURNAL OF CLINICAL ONCOLOGY
(2023)